首页 | 本学科首页   官方微博 | 高级检索  
检索        


Immune thrombocytopenic purpura in pregnancy: the ongoing debate surrounding obstetric management
Institution:1. Department of Obstetrics and Gynecology, John Peter Smith Hospital, Fort Worth, Texas, USA;1. Key Laboratory of Animal Disease-Resistance Nutrition and Feed Science, Ministry of Agriculture, PR China;2. Institute of Animal Nutrition, Sichuan Agricultural University, Ya׳an, 625014, PR China;1. Centro de Investigación y Tecnología Química (CITeQ), UTN – CONICET, Maestro López esq. Cruz Roja Argentina, 5016 Córdoba, Argentina;2. Departamento de Físico Química, Facultad de Ciencias Químicas, Universidad de Concepción, Concepción, Chile;3. Millenium Nuclei on Catalytic Processes towards Sustainable Chemistry (CSC), Chile
Abstract:Thrombocytopenia is a common hematologic complication of pregnancy. Most cases are the result of gestational thrombocytopenia, which poses no threat to mother or fetus. In contrast, other cases may be secondary to immune thrombocytopenic purpura (ITP), which may cause significant hemorrhagic morbidity in both. For this reason, diagnosing and treating ITP in pregnancy is important. The medical management of the disease is well established and has changed little. Conversely, obstetric management protocols have changed a great deal as our perception of fetal risk has been altered. Throughout the 1990s, many authors have reviewed the literature and challenged the existing belief that ITP is frequently associated with significant fetal morbidity. This has forced a revision of previous obstetric management recommendations. Despite evidence provided by these recent reviews, obstetric management of ITP in pregnancy remains an area of considerable controversy.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号